Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity

Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity

Background Although immune checkpoint inhibitors have been a breakthrough in clinical oncology, these therapies fail to produce durable responses in a significant fraction of patients. This lack of long-term efficacy may be due to a poor pre-existing network linking innate and adaptive immunity. Her...

Full description

Bibliographic Details
Main Authors: Alfred Zippelius, Mélanie Buchi, Richard Klar, Julia Festag, Sven Michel, Frank Jaschinski, Sebastian Kobold, Abhishek S Kashyap, Johannes vom Berg, Laura Fernandez-Rodriguez, Chiara Cianciaruso, Ruben Bill, Marcel P Trefny, Nicole Kirchhammer, Rainer H Kohler, Elham Jones, Andre Maaske, Karen O Dixon, Mikael J Pittet
Format: Article
Language:English
Published: BMJ Publishing Group 2023-05-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/11/5/e006714.full

Similar Items

Similar Items